The diabetic foot, stands out among the most feared complications (20% of diabetic patients will have ulcers on their feet at any time of their life) and it is therefore one of the main causes of physical-motor handicaps. It is known that 50% of major amputations are related to diabetes mellitus and its neurovascular complications, with a high economic and social cost.
Cuba has successfully developed a unique new drug to treat diabetic foot ulcers: Heberprot-P®. It is a lyophilized product, sterile, white color, without preservatives, for parenteral consumption. This product contains recombinant human epidermal growth factor, 75 μg / ampoule.
From the first contacts to the surgery, not to mention the transportation and the accomodation, discover the complete Medika guidance!